[go: up one dir, main page]

WO2001077169A3 - Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches - Google Patents

Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches Download PDF

Info

Publication number
WO2001077169A3
WO2001077169A3 PCT/US2001/011208 US0111208W WO0177169A3 WO 2001077169 A3 WO2001077169 A3 WO 2001077169A3 US 0111208 W US0111208 W US 0111208W WO 0177169 A3 WO0177169 A3 WO 0177169A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polypeptides
growth factor
stem cell
cell growth
Prior art date
Application number
PCT/US2001/011208
Other languages
English (en)
Other versions
WO2001077169A2 (fr
WO2001077169A9 (fr
Inventor
Tom Y Tang
Ivan Labat
Radoje T Drmanac
Nancy K Mize
Mitsuo Nishikawa
Cheng-Chi Chao
Original Assignee
Kirin Brewery
Tom Y Tang
Ivan Labat
Radoje T Drmanac
Nancy K Mize
Mitsuo Nishikawa
Cheng-Chi Chao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery, Tom Y Tang, Ivan Labat, Radoje T Drmanac, Nancy K Mize, Mitsuo Nishikawa, Cheng-Chi Chao filed Critical Kirin Brewery
Priority to JP2001575639A priority Critical patent/JP2003530124A/ja
Priority to EP01932523A priority patent/EP1268543A2/fr
Priority to AU5904101A priority patent/AU5904101A/xx
Priority to CA002405104A priority patent/CA2405104A1/fr
Publication of WO2001077169A2 publication Critical patent/WO2001077169A2/fr
Publication of WO2001077169A3 publication Critical patent/WO2001077169A3/fr
Publication of WO2001077169A9 publication Critical patent/WO2001077169A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux polynucléotides et polypeptides codés par ces polynucléotides et des mutants ou variants de ceux-ci qui correspondent à un nouveau polypeptide sécrété humain du type facteur de croissance de cellules souches. Ces polynucléotides comprennent des séquences d'acide nucléique isolées à partir de bibliothèques d'ADNc préparées à partir de cellules de testicules humains (numéros d'identification de clone Hyseq 2880984 et 2881695), de peau de foetus humains (numéro d'identification de clone Hyseq 15375176), de rates d'adulte (numéro d'identification de clone Hyseq 14856094) et de cellules endothéliales humaines (numéros d'identification de clone Hyseq 13804756, 13687487, 13804756). D'autres aspects de l'invention concernent des vecteurs contenant des processus pour produire de nouveaux polypeptides humains du type facteur de croissance de cellules souches, ainsi que des anticorps spécifiques de ces polypeptides.
PCT/US2001/011208 2000-04-05 2001-04-05 Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches WO2001077169A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001575639A JP2003530124A (ja) 2000-04-05 2001-04-05 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質
EP01932523A EP1268543A2 (fr) 2000-04-05 2001-04-05 Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches
AU5904101A AU5904101A (en) 2000-04-05 2001-04-05 Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides
CA002405104A CA2405104A1 (fr) 2000-04-05 2001-04-05 Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US54377400A 2000-04-05 2000-04-05
US09/543,774 2000-04-05
US21573300P 2000-06-28 2000-06-28
US60/215,733 2000-06-28
US75756201A 2001-01-09 2001-01-09
US09/757,562 2001-01-09
US26661401P 2001-02-05 2001-02-05
US60/266,614 2001-02-05

Publications (3)

Publication Number Publication Date
WO2001077169A2 WO2001077169A2 (fr) 2001-10-18
WO2001077169A3 true WO2001077169A3 (fr) 2002-07-04
WO2001077169A9 WO2001077169A9 (fr) 2002-12-19

Family

ID=27499020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011208 WO2001077169A2 (fr) 2000-04-05 2001-04-05 Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches

Country Status (5)

Country Link
EP (1) EP1268543A2 (fr)
JP (1) JP2003530124A (fr)
AU (1) AU5904101A (fr)
CA (1) CA2405104A1 (fr)
WO (1) WO2001077169A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
JP2005514917A (ja) * 2001-10-03 2005-05-26 インサイト・ゲノミックス・インコーポレイテッド 分泌タンパク質
PT2157192E (pt) 2003-10-10 2013-11-28 Deutsches Krebsforsch Composições para diagnóstico e terapia de doenças associadas com a expressão aberrante de futrinas (r-espondinas)
WO2005072419A2 (fr) 2004-01-27 2005-08-11 Nuvelo, Inc. Facteur proliferatif gastro-intestinal et utilisations de celui-ci
US7541431B2 (en) 2005-09-07 2009-06-02 Maine Medical Center Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
EP1942926A4 (fr) * 2005-10-07 2010-06-16 Nuvelo Inc Scfa1, protéine du type facteur des cellules souches et utilisations de celle-ci
SI2066694T1 (sl) 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
JP5777281B2 (ja) 2006-10-20 2015-09-09 デウトスクフエス クレブスフオルスチュングスゼントルム ストイフトウング デス オフフエントリクヘンレクフトス 血管新生及び脈管形成のモジュレーターとしてのｒスポンジン
WO2008075796A1 (fr) * 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. Agent pour encourager la récupération après une déplétion de globule sanguin
PL2173379T3 (pl) 2007-07-02 2016-02-29 Oncomed Pharm Inc Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
EP2412800A1 (fr) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Organoïde du foie, ses utilisations et son procédé de culture pour l'obtenir
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
HRP20160791T1 (hr) 2009-02-03 2016-09-23 Koninklijke Nederlandse Akademie Van Wetenschappen Kultivirani medij za epitelne matične stanice i organoidi koji sadrže navedene matične stanice
WO2010121923A1 (fr) 2009-04-15 2010-10-28 Deutsches Krebsforschungszentrum Inhibition de la rspondine-3 dans des troubles osseux
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
MX349198B (es) 2011-07-15 2017-07-18 Oncomed Pharmaceuticals Inc * Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
KR102100307B1 (ko) * 2012-03-21 2020-04-14 다나-파버 캔서 인스티튜트 인크. 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도
SG11201500233PA (en) 2012-07-13 2015-04-29 Oncomed Pharm Inc Rspo3 binding agents and uses thereof
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
CN108607101A (zh) * 2018-05-04 2018-10-02 广西中医药大学附属瑞康医院 Zip1基因在制备抑制骨髓间充质干细胞凋亡的产品中的应用
CN111420034A (zh) * 2019-01-08 2020-07-17 上海莱馥医疗科技有限公司 一种用于治疗银屑病的混合干细胞制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049302A1 (fr) * 1997-04-25 1998-11-05 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
WO2000056755A1 (fr) * 1999-03-19 2000-09-28 Human Genome Sciences, Inc. Proteines humaines secretees (49)
WO2001040294A1 (fr) * 1999-11-29 2001-06-07 Bioroad Gene Development Ltd. Shanghai Nouveau polypeptide, thrombospondine humaine 30, et polynucleotide codant pour ce polypeptide
WO2001057190A2 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049302A1 (fr) * 1997-04-25 1998-11-05 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
WO2000056755A1 (fr) * 1999-03-19 2000-09-28 Human Genome Sciences, Inc. Proteines humaines secretees (49)
WO2001040294A1 (fr) * 1999-11-29 2001-06-07 Bioroad Gene Development Ltd. Shanghai Nouveau polypeptide, thrombospondine humaine 30, et polynucleotide codant pour ce polypeptide
WO2001057190A2 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200142, Derwent World Patents Index; Class B04, AN 2001-397948, XP002183188 *
See also references of EP1268543A2 *
SZILVASSY S J ET AL: "LEUKEMIA INHIBITORY FACTOR UPREGULATES CYTOKINE EXPRESSION BY A MURINE STROMAL CELL LINE ENABLING THE MAINTENANCE OF HIGHLY ENRICHED COMPETITIVE REPOPULATING STEM CELLS", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 87, no. 11, 1 June 1996 (1996-06-01), pages 4618 - 4628, XP000971084, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2001077169A2 (fr) 2001-10-18
CA2405104A1 (fr) 2001-10-18
JP2003530124A (ja) 2003-10-14
WO2001077169A9 (fr) 2002-12-19
EP1268543A2 (fr) 2003-01-02
AU5904101A (en) 2001-10-23

Similar Documents

Publication Publication Date Title
WO2001077169A3 (fr) Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches
WO2001088092A3 (fr) Procedes et materiaux relatifs aux polypeptides et polynucleotides du type facteur des cellules souches (du type fcs)
CA2253238A1 (fr) Nouveau gene apparente a l'agouti
WO2000075350A3 (fr) Sequences d'acide nucleique codant des proteines impliquees dans la beta-oxydation des acides gras et procedes d'utilisation
EP0332104A3 (fr) Sèquences d'ADN et gènes chimiquement regulables, et leur emploi
EP1624065A3 (fr) Agarase et gène correspondant
WO1997043409A3 (fr) Procede d'obtention de nouvelles sequences d'adn
WO2001055336A3 (fr) Procedes et substances relatifs a des polypeptides de type cd84 et a des polynucleotides
WO1995006735A3 (fr) Sequences nucleotidiques servant a coder de nouvelles tyrosine-phosphatases proteiques
WO2001053454A3 (fr) Procedes et elements ayant trait a des polypeptides et des polynucleotides de type recepteurs couples a une proteine g
WO2003029405A3 (fr) Procedes et materiaux relatifs aux polynucleotides et polypeptides de type facteur de croissance de cellules souches
WO2001053500A8 (fr) Procedes et substances relatifs a des polypeptides de type facteur de croissance de cellules souches et a des polynucleotides
WO2001044276A3 (fr) Genes de mousse de physcomitrella patens codant pour des proteines impliquees dans la synthese de tocopherols et de carotenoides
WO2001031029A3 (fr) Gene de la sphingosine kinase humaine
EP1574520A3 (fr) Polypeptides et polynucléotides ressemblant à la molécule de guidage neuronale ainsi que méthodes et matériaux dérivés
WO2001055335A3 (fr) Procedes et materiaux se rapportant a des polypeptides et polynucleotides semblables a des recepteurs de leucocytes de type immunoglobuline (lir)
WO1997002730A3 (fr) Polypeptide associe a une matrice d'email
WO1988009378A3 (fr) Polypeptide code par un oncogene et presentant une activite de facteur de croissance, ses procedes de production et d'utilisation
WO2000004041A3 (fr) Procedes et materiaux associes a de nouveaux polypeptides semblables a cd39
WO2001055332A3 (fr) Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides de type regulateur de croissance
WO1999045107A8 (fr) Nouvelle proteine calpaine et adn codant ladite proteine
WO2001057233A3 (fr) Methodes et materiaux associes a des polypeptides et des polynucleotides du type facteur-1 des preadipocytes (du type pref-1)
WO2001075064A3 (fr) Methode et materiels relatifs a des polypeptides et a des polynucleotides semblables a la proteine de liaison au facteur de croissance semblable a l'insuline
WO2001055337A3 (fr) Procedes et substances relatifs a des polypeptides de type antigene carcino-embryonnaire (cea) et a des polynucleotides
CA2284101A1 (fr) Desoxyribonucleoside-kinase de cellules d'insecte pour la synthese de nucleoside-monophosphates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2405104

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 575639

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001932523

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 197, CLAIMS, REPLACED BY A NEW PAGE 197; PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2001932523

Country of ref document: EP